Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 21, 2026 · Filed Oct 21, 2026
The CFO of Rapport Therapeutics paid $144K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in 19 months.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Written by software from the filings listed below · Oct 23, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeopen market purchase
Code P — open-market or private purchase
~$143,550
Shares × reported transaction price
$100K–$500K
+55.0%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 19 months
Confirmed open-market purchases by the same insider in the available history
Yes
Compared with 2 earlier confirmed purchases
7 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
77 days after results of Aug 5, 2026, 9 days before results of Oct 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $25.06 on Oct 21, 2026, within 3% of its 52-week low, after a 43% drop over the previous 30 trading days
52-week range $24.37 (Nov 14, 2025) to $52.50 (Aug 26, 2026), 2% of the way up, from 250 adjusted closes. 30 trading days earlier: $43.89 on Sep 9, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 7 days before RAPP reported its results (Oct 28, 2026). The first open-market purchase by any RAPP insider since Sep 2025. Troy A. Ignelzi's largest purchase of RAPP in their filings since 2025
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −8.7% | +0.7% | −9.4% |
Past results only. Not a forecast.
Insider filing
Traded Oct 30 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 30 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
7 days before resultsTraded Oct 28 · filed 2 days later
A Rapport Therapeutics director paid $79K out of pocket for Rapport Therapeutics shares. 6 other people at Rapport Therapeutics bought some too, in the same month. It was the first purchase in over a year.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
